# Kai Wu

> Kai Wu is a Series A investor at CICC (Shanghai) backing Medical and Health Care. See 3 investments, check sizes, portfolio. Updated Aug 2026.

- Type: Angel Investor
- Fund: [CICC](https://shizune.co/investors/profile/cicc)
- Location: Shanghai, China
- Total investments: 3
- Last investment: Jun 2022
- Lead investor: 33%
- Last updated: Aug 2026
- LinkedIn: https://cn.linkedin.com/in/kai-wu-527017159

Kai Wu is a Series A investor at CICC in Shanghai focused on Medical and Health Care. Wu Kai is working as Vice President for CICC Capital.

## Investment focus

### Industry

| Industry | Investments | Share |
| --- | --- | --- |
| Medical | 1 | 33% |
| Health Care | 1 | 33% |
| Therapeutics | 1 | 33% |
| Biotechnology | 1 | 33% |
| Manufacturing | 1 | 33% |

9 industries tracked in total.

### Stage

| Stage | Investments | Share |
| --- | --- | --- |
| Series A | 2 | 67% |
| Series B | 1 | 33% |

## Investments

| Company | Description | Amount | Stage | Date | Website |
| --- | --- | --- | --- | --- | --- |
| Kingwills New Materials | The main business of "Qingyun New Materials" is to develop, produce and sell flash-spun metamaterial Kunlun® Hypak® , which is a high-strength, waterproof and breathable special fiber material that is arranged in the form of non-woven fabrics. | $14.8M | Series A | Jun 14, 2022 |  |
| Xinjunte | Xinjunte has focused on the research and development of intelligent medical devices for bone surgery, and is committed to providing more efficient and safe medical devices. |  | Series B | Nov 01, 2021 |  |
| Reforgene Medicine | Reforgene Medicine is a biomedical company that uses gene editing and genomic technology to develop new drugs intended to cure genetic diseases. |  | Series A | Sep 16, 2021 |  |

3 of 3 investments shown.

## Co-investors
- [ABC International](https://shizune.co/investors/profile/abc-international) — VC Fund, 1 deal together
- [Asia Green Fund](https://shizune.co/investors/profile/asia-green-fund) — VC Fund, 1 deal together
- [Oriental Yuhong](https://shizune.co/investors/profile/beijing-oriental-yuhong-waterproof-technology) — VC Fund, 1 deal together
- [BioTrack Capital](https://shizune.co/investors/profile/biotrack-capital) — VC Fund, 1 deal together
- [BioVenture](https://shizune.co/investors/profile/bioventure) — VC Fund, 1 deal together
- [China Merchants Securities](https://shizune.co/investors/profile/china-merchants-securities) — VC Fund, 1 deal together

## About CICC

VC Fund · Beijing, China

Established in 1995 as the first joint venture investment bank in China, China International Capital Corporation Limited (CICC) is a leader in providing comprehensive financial services including investment banking, capital markets, institutional and individual securities sales and trading, fixed income, asset management, private equity, individualwealth management and research.

5 contacts available at CICC.

| Name | Title | Profile |
| --- | --- | --- |
| David Zhang | Vice President | https://shizune.co/investors/profile/david-zhang-8 |
| Jiang, Xingquan | Managing Director | https://shizune.co/investors/profile/jiang-xingquan |
| Kai Wu | Vice President | https://shizune.co/investors/profile/kai-wu-c62a |
| Lei Yin | Vice President; Executive Director | https://shizune.co/investors/profile/lei-yin-bc3b |
| Levin Zhu | CEO & President | https://shizune.co/investors/profile/levin-zhu |

## Similar investors

### Similar stage
- [Antler](https://shizune.co/investors/profile/antler-be9c) — VC Fund
- [Alumni Ventures](https://shizune.co/investors/profile/alumni-ventures-group) — VC Fund
- [General Catalyst](https://shizune.co/investors/profile/general-catalyst-partners) — VC Fund

## FAQ

### What does Kai Wu invest in?

Kai Wu invests primarily in Medical, Health Care and Therapeutics startups, most often at Series A and Series B stage. Most of the 3 investments tracked by Shizune back companies in China. The Investment Focus section breaks down every industry, stage and country in the portfolio.

### When did Kai Wu last invest?

The most recent investment recorded for Kai Wu closed in Jun 2022. Shizune tracks 3 investments in total for this profile, including round sizes, stages and portfolio companies, all sourced from confirmed public funding rounds and refreshed monthly.

### Is Shizune's investor data accurate?

Yes — every stat on this profile is calculated from confirmed public funding rounds monitored across hundreds of sources since 2020. This profile was last refreshed in Aug 2026 and is updated monthly. Spotted something off? Use the “Suggest an edit” link near the top of the page.

# About Shizune
Shizune.co is an investor database. Core features:
- 48,091 startup investors (angels, VCs, accelerators, and others)
- Email, phone, LinkedIn (for intros), socials, and other contact data
- Updated daily from public funding news
- CSV and Excel export

The User can access the full database FOR FREE after signing up: shizune.co